Dear everyone,
Here is a time-limited open-access link for the Darwin’s 30-year paper at LID.
Your personalized Share Link:
https://authors.elsevier.com/a/1dSG25E-UoV3iS
So, feel free to grab the PDF file, if you are of interest.
BTW, our large behavior change trial is also released at PLoS NTD.
https://doi.org/10.1371/journal.pntd.0009060
I wish that 2022 will be so kind that we can meet F2F in Graz, can tell you all more about the work, and can also hear more about everyone’s works as well.
Please take good care of patients, yourself and your family.
Kind regards,
Direk
PS. Bart, thank you very much.
Our Darwin paper has finally seen the light of day after over a year since submission. I acknowledge the IMN and a link is provided so I hope readers join up.
It reflects all our long term collaborations and friendships.
Get
Outlook for iOS
From: Elsevier - Article Status <Article...@elsevier.com>
Sent: Friday, July 23, 2021 8:33 am
To: Bart Currie
Subject: Share your article [LANINF_3278] published in The Lancet Infectious Diseases
|
|
|
|
|
Dear Professor Currie,
We are pleased to let you know that your article
The Darwin Prospective Melioidosis Study: a 30-year prospective, observational investigation is now available online with author corrections incorporated. Full citation details, e.g. volume and/or
issue number, publication year and page numbers, will be added when the final version becomes available.
To help you access and share this work, we have created a Share Link – a personalized URL providing
50 days' free access to your article. Anyone clicking on this link before
September 10, 2021 will be taken directly to the latest version of your article on ScienceDirect, which they are welcome to read or download. No sign up, registration or fees are required.
|
|
|
|
|
We encourage you to use this Share Link to download a copy of the article for your own archive. The URL is also a quick and easy way to share your work with colleagues, co-authors and
friends. And you are welcome to add the Share Link to your homepage or social media profiles, such as Facebook and Twitter.
You can find out more about Share Links on
Elsevier.com.
Did you know, as an author, you can use your article for a wide range of scholarly, non-commercial purposes, and share and post your article online in a variety of ways? For more information
visit
www.elsevier.com/sharing-articles.
Kind regards,
Elsevier Researcher Support
|
|
|
Increase your article's impact
Our
Get Noticed guide contains a range of practical tips and advice to help you maximize visibility of your article.
Publishing Lab
Do you have ideas on how we can improve the author experience? Sign up for the
Elsevier Publishing Lab and help us develop our publishing innovations!
Have questions or need assistance?
Please do not reply to this automated message.
For further assistance, please visit our
Elsevier Support Center where you search for solutions on a range of topics and find answers to frequently asked questions.
You can also talk to our researcher support team by phone 24 hours a day from Monday-Friday and 24/7 by live chat and email.
© 2021 Elsevier Ltd | Privacy Policy
http://www.elsevier.com/privacypolicy
Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, United Kingdom, Registration No. 1982084. This e-mail has been sent to you from Elsevier Ltd. To ensure delivery to your inbox (not bulk or junk folders), please add
article...@elsevier.com to your address book or safe senders list.
|
|
